par Duffaud, F;van der Burg, Maria;Namer, Moïse;Vergote, Ignace;Willemse PHB, B;ten Bokkel Huinink, Wim;Guastalla, Jean Paul;Nooij, j;Kerbrat, Pierre;Piccart-Gebhart, Martine 
;Tumolo, Salvatore;Favalli, Giuseppe;van der Vange, N;Lacave, Ángel Jiménez;Wils, J;Splinter, Ted;Einhorn, N;Roozendaal, K J;Rosso, Riccardo;Vermorken, Jan Baptist
Référence Anti-cancer drugs, 12, 2, page (159-162)
Publication Publié, 2001-02
;Tumolo, Salvatore;Favalli, Giuseppe;van der Vange, N;Lacave, Ángel Jiménez;Wils, J;Splinter, Ted;Einhorn, N;Roozendaal, K J;Rosso, Riccardo;Vermorken, Jan BaptistRéférence Anti-cancer drugs, 12, 2, page (159-162)
Publication Publié, 2001-02
Article révisé par les pairs
| Résumé : | Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients. The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months. The treatment was well tolerated; the only reported adverse events were incidental hot flushes. This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy. |
